Results 251 to 260 of about 195,924 (307)

Quality of life following total neoadjuvant therapy for rectal cancer. [PDF]

J Cancer Res Clin Oncol
Wurschi GW, Diefenhardt M, Kaufmann J, Ha HM, Schneider M, von Ohlen DS, Schöneich M, Cieslak A, Depardon A, Becker JN, Rühle A, Ehret F, Römer M, Rißner F, Hinz A, Pietschmann K.   +15 more
europepmc   +1 more source

Selecting patients with rectal cancer for total neoadjuvant therapy based on clinical lymph node status: do we dare? [PDF]

Acta Oncol
Slipsager AB, Lauritzen MB, Buskov LK, Poulsen LØ.   +3 more
europepmc   +1 more source

Factors Driving Attrition from Neoadjuvant Therapy to Pancreatectomy in Localized Pancreatic Cancer. [PDF]

Ann Surg Oncol
Dickey EM, Min L, Dhawan A, Martos M, Franceschi D, Livingstone AS, Hosein P, Terrero G, Datta J, Merchant N, Hester C.   +10 more
europepmc   +1 more source

Editorial: The role of adjuvant and neoadjuvant therapy in resectable esophageal cancer. [PDF]

Front Oncol
Li X, Cong Z, Qiang Y.
europepmc   +1 more source

Neoadjuvant Radiochemotherapy and Total Neoadjuvant Therapy in the Management of Locally Advanced Rectal Cancer. [PDF]

Cureus
Yigit M, Roohani S, Kurreck A, Siegel R, Modest DP, Kaul D, Ehret F.   +6 more
europepmc   +1 more source

Association of Tumor-Infiltrating Lymphocytes (TILs) With Pathological Complete Response to Neoadjuvant Therapy in Breast Cancer. [PDF]

Cureus
Ul Ain N, Ishaq S, Islam MK, Badar Q, Chaudhry K, Adil T, Bangash SA.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Neoadjuvant therapy for pancreatic cancer

Nature Reviews Clinical Oncology, 2023
Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with surgical resection of the primary tumour and systemic chemotherapy, which provides considerably longer overall survival (OS) durations than either modality alone. Regardless, most patients will have disease relapse owing to micrometastatic disease.
Christoph Springfeld, Cristina R. Ferrone, Matthew H. G. Katz, Philip A. Philip, Theodore S. Hong, Thilo Hackert, Markus W. Büchler, John Neoptolemos   +7 more
openaire   +4 more sources

Neoadjuvant Therapy for Melanoma

Surgical Oncology Clinics of North America, 2020
With the universal adoption of immune checkpoint blockade and agents targeting BRAF-mutated melanomas in the metastatic setting, numerous clinical trials have evaluated these agents in the neoadjuvant setting. These smaller trials have shown promising results with high pathologic response rates and acceptable safety.
Michael C, Lowe, Ragini R, Kudchadkar
openaire   +2 more sources

Neoadjuvant Therapy for Rectal Cancer

Surgical Oncology Clinics of North America, 2022
The treatment of locally advanced rectal cancer is challenging and requires a multidisciplinary approach. Neoadjuvant treatment has improved local control by the combination of radiotherapy, surgery, and chemotherapy. However, neoadjuvant treatment has not yet been shown to improve overall survival and is associated with toxicities and late sequelae ...
Felipe F, Quezada-Diaz, J Joshua, Smith
openaire   +2 more sources